Venturing into ophthalmic space

Venturing into ophthalmic space

Company Type Date Raised Description
Alacrity Biosciences Debt 3/5/07 $8.5 Developing compounds to treat ocular surface diseases, glaucoma and retinal disease. Lead compound is ALTY-0501, a topical formulation of doxycycline that has completed a Phase II trial.
Alimera Sciences Series C 3/18/08 $30.0 Focused on diseases that affect the back of the eye (retina). Lead compound is Iluvien,

Read the full 761 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE